Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial

BACKGROUND: The COVID-19 pandemic caused a wave of acute respiratory distress syndrome (ARDS) with a high in-hospital mortality, especially in patients requiring invasive mechanical ventilation. Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) may counteract the pulmonary damage induced by...

Descripción completa

Detalles Bibliográficos
Autores principales: Pochon, Cécile, Laroye, Caroline, Kimmoun, Antoine, Reppel, Loic, Dhuyser, Adéle, Rousseau, Hélène, Gauthier, Mélanie, Petitpain, Nadine, Chabot, Jean-François, Valentin, Simon, de Carvalho Bittencourt, Marcelo, Peres, Michael, Aarnink, Alice, Decot, Véronique, Bensoussan, Danièle, Gibot, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495568/
https://www.ncbi.nlm.nih.gov/pubmed/37706025
http://dx.doi.org/10.3389/fmed.2023.1224865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495568/
https://www.ncbi.nlm.nih.gov/pubmed/37706025
http://dx.doi.org/10.3389/fmed.2023.1224865

Ejemplares similares